log  
logo
A Journal of Postdoctoral Research.
 
     Login   |   Register   
    ISSN : 2328-9791
left right
 
 
Preclinical development of the antimicrobial peptide M33 and onset of regulatory procedur
     
 
Pini A
Università di Siena
Dip. di Biotecnologie Mediche, Università di Siena, Italy.
info@postdocjournal.com

Background. This is a project aimed at the pharmaceutical development of a new antimicrobial peptide (M33) discovered at the University of Siena. M33 showed a strong activity in vitro and in vivo against a panel of bacteria generally involved in CF infections.

Hypothesis and objectives. Before arriving to human experimentation, a new drug must be developed preclinically and this includes the study of pharmacokinetic, bio-distribution and toxicity profiles in animals. This project was exactly designed for the evaluations of these issues. At the end of preclinical procedures of development, regulatory documents for the request of a Clinical Trial Authorization will be submitted to competent authorities.

 
btm
 
top
 
 
 
 
 
btm

 
footer
 
 
home phone mail info@postdocjournal.com
 
twitter facebook social icon Social link You Tube sky
Click Here